Advanced Prostate Cancer VL

Use of Conservative Management for Low-Risk Prostate Cancer - Interview with Stacy Loeb

Details
(Length of Discussion: 7 min) Stacy Loeb, MD, and Alicia Morgans, MD discuss conservative management, active surveillance, and management trends over time for low-risk prostate cancer in the Veterans Affairs Integrated Health Care System over the past decade. Biographies: Stacy Loeb, MD, is an Assistant Professor of Urology and Population Health at New York University (NYU), specializing in prosta...

Dedication to Multidisciplinary Management of GU Oncology - Alex Kutikov

Details
(Length of Conversation: 10 min) Alex Kutikov, MD, FACS talks with Alicia Morgans, MD, MPH on the multidisciplinary management of genitourinary oncology and his experiences at Fox Chase Cancer Center. This discussion includes the importance of the collaborative care for the patient from the radiation oncologist, medical oncologist, and urologist and the nuances of this co-management with the numbe...

Clinical Implications of the Abi Race Study: Interview with Dan George

Details
(Length of Discussion: 12 min) Daniel George, MD talks with Charles Ryan, MD and discusses a number of recent studies Daniel and his colleagues at Duke University School of Medicine have been focused on related to race and abiraterone outcomes in prostate cancer patients and how this new information impacts clinical practice. Studies and Presentations Discussed in Discussion: Overall Survival Betw...

The RADICAL PC Project - Jehonathan Pinthus

Details
(Length of Presentation: 20 min) Jehonathan Pinthus presents the role of androgen deprivation therapy (ADT) in promoting cardiovascular disease (CVD) and focuses on two prospective studies, one of which is embedded in the other. The Role of Androgen Deprivation Therapy in Cardiovascular Disease – A Longitudinal Prostate Cancer Study (RADICAL PC1) is a prospective cohort study of men within one yea...

New Concepts in ADT- Thomas Keane

Details
(Length of Discussion: 21 min) Tom Keane brings new concepts in androgen deprivation therapy (ADT) to light specifically discussing agonists versus antagonists, new androgen receptor-targeted drugs, including immunotherapy biomarkers, and genomic testing. He reviews the current state of the CRPC treatment and ADT options for use in advanced metastatic disease and concludes with a discussion on tre...

Quality of Life During Treatment with Chemohormonal Therapy - Alicia Morgans

Details
Alicia Morgans, MD and Charles Ryan, MD discuss the quality of life between patients with metastatic hormone-sensitive prostate cancer who were treated with ADT+docetaxel and those who were treated with ADT alone. The importance of the study was to understand how different treatments actually affected the individuals receiving them. Biographies: Alicia Morgans, MD, MPH Charles J. Ryan, MD Read Mor...

Neoadjuvant Therapy for Men with High Risk Disease Prior to Prostatectomy - Mary-Ellen Taplin

Details
(Length of Conversation: 19 min) Mary-Ellen Taplin, MD, and Alicia Morgans, MD discuss the topic of neoadjuvant therapy for men with high-risk disease prior to surgery, specifically, prior to prostatectomy. Among the topics discussed include the importance of studying neoadjuvant chemotherapy and hormonal therapies in clinical trials before being used more broadly in everyday clinical practice, pa...

Discussion on FALCON: Impact of 18F-fluciclovine PET/CT on Clinical Management Choices for Men with Biochemically Recurrent Prostate Cancer

Details
(Length of Discussion: 4 min) Dr. Thomas Keane provides a commentary on the The FALCON Trial , the impact of 18F-fluciclovine PET/CT on clinical management choices for men with biochemically recurrent prostate cancer presented at the recent 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium . Eugene Jueren Teoh, MBBS, MRCP from the University of Oxford presented t...

The Past, Present, and Future Approaches to Prostate Biopsies - Baris Turkbey

Details
Dr. Baris Turkbey, Associate Research Physician of the Molecular Imaging Program at the National Cancer Institute, shares the past, present, and future approaches to prostate biopsies. Dr. Turkbey states that TRUS (Transrectal Ultrasound aka Systemic) biopsies have been the “standard of care” after PSA elevation for the past 25 years. However, prostate imaging is not always preceding biopsy. MRI p...

IRONMAN - A Better Understanding of the Variation in Care and Treatment - Daniel George

Details
(Length of Discussion: 17 min) Daniel George, MD and Director of GU Oncology talks with Alicia Morgans, MD about the IRONMAN initiative. The intent of the project was to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of a minimum of 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe